X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the terms of the agreement, Wistar grants Active Biotech a global exclusive license to develop and commercialize tasquinimod in combination therapy, as a treatment for multiple myeloma.
Lead Product(s): Tasquinimod,Ixazomib Citrate,Lenalidomide
Therapeutic Area: Oncology Product Name: ABR-215050
Highest Development Status: Phase IProduct Type: Small molecule
Recipient: Wistar Institute of Anatomy and Biology
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition May 22, 2024
Details:
Laquinimod is a first-in-class immunomodulator that induces immune tolerance and reduces the pro-inflammatory and angiogenic response by targeting of the myeloid cell compartment.
Lead Product(s): Laquinimod
Therapeutic Area: Ophthalmology Product Name: TV-5600
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 26, 2022
Details:
Under the terms of the agreement, Oncode Institute, a foundation under the laws of the Netherlands, acting on behalf of Erasmus Universiteit Medisch Centrum, grants a global exclusive license to develop and commercialize tasquinimod worldwide in MF to Active Biotech.
Lead Product(s): Tasquinimod
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Oncode Institute
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement February 09, 2022
Details:
Preclinical data on drug tasquinimod, a small molecule immunomodulator Targets Immunosuppressive Myeloid Cells, Increases Osteogenesis and Has Direct Anti-Myeloma Effects by Inhibiting c-Myc Expression in Vitro and In Vivo.
Lead Product(s): Tasquinimod
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 15, 2021
Details:
A preclinical program shows that the laquinimod eye-drop is safe and well tolerated, and the safety of this new formulation will now be tested in a phase I clinical study in healthy subjects.
Lead Product(s): Laquinimod
Therapeutic Area: Ophthalmology Product Name: ABR-215062
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 10, 2021
Details:
Naptumomab estafenatox (NAP) is a cell therapy candidate, currently in Phase I. It is in clinical development for advanced solid tumors utilizing its proprietary Tumor Targeted Superantigen platform.
Lead Product(s): Naptumomab Estafenatox,Durvalumab
Therapeutic Area: Oncology Product Name: ABR-217620
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: NeoTX Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 30, 2021
Details:
Tasquinimod is an oral immunomodulatory and anti-angiogenic investigational treatment, that affects the tumor’s ability to grow and metastasize. Tasquinimod is developed as a new immunomodulatory treatment for multiple myeloma.
Lead Product(s): Tasquinimod,Ixazomib Citrate,Lenalidomide
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 03, 2021
Details:
The study was amended to also include assessment of pre-treatment with obinutuzumab to assess its effect on anti-drug antibodies (ADAs) to naptumomab.
Lead Product(s): Naptumomab Estafenatox,Durvalumab
Therapeutic Area: Oncology Product Name: NAP
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: NeoTX Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 05, 2021
Details:
Through the agreement, Active Biotech will get the material for the clinical development of the eye-drop formulation of ABR-215062 (laquinimod), which is used for the treatment of non-infectious non-anterior uveitis.
Lead Product(s): Laquinimod
Therapeutic Area: Ophthalmology Product Name: ABR-215062
Highest Development Status: Phase IProduct Type: Small molecule
Recipient: Famar
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement February 04, 2021
Details:
In 2016, Active Biotech and NeoTX entered into a partnership for the development and commercialization of naptumomab in cancer indications.
Lead Product(s): Naptumomab estafenatox,Durvalumab
Therapeutic Area: Oncology Product Name: ABR-217620
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: NeoTX Therapeutics
Deal Size: $71.0 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement December 11, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
